Rocket Pharmaceuticals Stock Analysis

Rocket Stock Analysis Notes

About 92.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.12. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rocket Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 2.25. The firm last dividend was issued on the 5th of January 2018. Rocket Pharmaceuticals had 1:4 split on the 5th of January 2018. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. Rocket Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people. To find out more about Rocket Pharmaceuticals contact Gaurav MD at 609 659 8001 or learn more at https://www.rocketpharma.com.

Rocket Pharmaceuticals Investment Alerts

Rocket Largest EPS Surprises

View All Earnings Estimates

Rocket Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Rocket Stock Institutional Investors

Note, although Rocket Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Rocket Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 353.89 M.

Rocket Profitablity

Management Efficiency

Rocket Pharmaceuticals has return on total asset (ROA) of (0.4056) % which means that it has lost $0.4056 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7488) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2026. Return On Capital Employed is likely to drop to -0.68 in 2026. At this time, Rocket Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 28.6 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 314.9 M in 2026.

Technical Drivers

As of the 14th of February 2026, Rocket Pharmaceuticals holds the Coefficient Of Variation of 2985.06, risk adjusted performance of 0.0349, and Semi Deviation of 3.25. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rocket Pharmaceuticals, as well as the relationship between them.

Rocket Pharmaceuticals Price Movement Analysis

Rocket Pharmaceuticals Insider Trading Activities

Rocket Pharmaceuticals Outstanding Bonds

Rocket Pharmaceuticals Predictive Daily Indicators

Rocket Pharmaceuticals Forecast Models

Rocket Pharmaceuticals' time-series forecasting models are one of many Rocket Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rocket Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Rocket Pharmaceuticals Bond Ratings

Rocket Pharmaceuticals financial ratings play a critical role in determining how much Rocket Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Rocket Pharmaceuticals' borrowing costs.

Rocket Pharmaceuticals Debt to Cash Allocation

Rocket Pharmaceuticals currently holds 25.5 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Rocket Pharmaceuticals has a current ratio of 13.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rocket Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Rocket Pharmaceuticals Total Assets Over Time

Rocket Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Rocket Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Rocket Pharmaceuticals Debt Ratio

5.28

It appears most of the Rocket Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Rocket Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Rocket Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Rocket Pharmaceuticals Corporate Bonds Issued

Rocket Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Rocket Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rocket shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rocket Pharmaceuticals. By using and applying Rocket Stock analysis, traders can create a robust methodology for identifying Rocket entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rocket analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rocket analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Rocket Pharmaceuticals stock analysis indicators help investors evaluate how Rocket Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rocket Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rocket Pharmaceuticals stock analysis, traders can identify Rocket Pharmaceuticals position entry and exit signals to maximize returns.

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.